Freestone Grove Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Freestone Grove Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.3M	Buy	+39,806	New	+$5.38M	0.04%	328

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Freestone Grove Partners's XBI Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 39,806 shares worth $6.3M. The stake represents 0.04% of the portfolio and ranks #328 among its holdings.

932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Freestone Grove Partners held 39,806 shares of State Street SPDR S&P Biotech ETF worth $6.3M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Freestone Grove Partners position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.04% of Freestone Grove Partners's portfolio in Q2 2026, its #328 holding.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.